Researchers have developed a melanin-enhanced cancer immunotherapy technique that can also serve as a vaccine, based on early experiments done in a mouse model.
The technique is applied via a transdermal patch.
“There are a lot of immune cells in the skin, and the fundamental concept here is to train the body’s immune system to respond effectively to the presence of melanoma cells – which could both limit the likelihood of developing tumors and help the body fight off tumors that are already established,” says Yanqi Ye, lead author of the work and a Ph.D. student in the joint biomedical engineering program.
The new technique starts with a lysate – a tumor puree, made up of ruptured melanoma cells. The lysate is used to fill an array of microneedles, embedded in a polymeric transdermal patch.
By itself, the lysate is inactive and harmless.
But when the patch is applied to the skin, the largest immune organ of the body, the immune system knows that, whatever the lysate is, it shouldn’t be there.
This triggers an immune response, and that response allows the immune system to “remember” the melanoma lysate, improving its response time and efficiency should it encounter melanoma again.
Because melanoma contains high levels of the pigment melanin, the lysate-filled microneedles are fairly dark in color.
They absorb light.
The researchers take advantage of that in their new technique, shining near IR light onto the transdermal patch.
The light is then largely absorbed by the melanin in the microneedles, which quickly raises the temperature of the skin where the patch is applied.
The local heat causes a fever-like environment in the skin and promotes the release of lysate from the microneedles, effectively attracting and activating immune cells.
The increased temperature also contributes to the locally increased blood and lymphatic flow that facilitates the migration of immune cells.
This increased immune response amplifies the ability of the body to remember – and respond to – the lysate, better protecting against incursions of melanoma.
To test the patch’s potential as a vaccine, the researchers used three groups of mice:
one group got the patch and was exposed to IR light;
one group got the patch, but was not exposed to IR light;
and one group got an empty patch. The mice had the patch on for five days. Ten days after the patch was applied, mice were injected with active melanoma cells.
Within one month, all of the mice who received the empty patch had died from melanoma.
The lysate patch by itself, without exposure to near IR light, provided little protection: only 13 percent of the mice survived.
Meanwhile, 100 percent of the mice that got the lysate patch and IR light survived after two months- and 87 percent of them had no tumors.
To further test the patch’s therapeutic properties, researchers performed a similar experiment.
Except this time, all of the mice had already developed two tumors – one on each side of the body. The patch was placed on the tumor on the left side of their bodies.
Mice that received the lysate patch and IR light saw significant decreases in tumor volume for both tumors, though the tumor on the left (the one directly under the patch) shrank more.
The patch by itself, without IR light, limited tumor growth – particularly on the left – but did not eradicate it.
“This demonstrates that the technology could have potential in targeting both cancer metastasis and primary tumors,” says Gianpietro Dotti, coauthor of the study and a professor in the University of North Carolina School of Medicine.
The researchers then ran similar experiments using lysate made from two other cancers – breast cancer and a second form of melanoma with limited melanin.
In both cases, the researchers added melanin to the lysate to make it more light absorbent.
The results were similar to those from the first form of melanoma:
patches used in conjunction with near IR light got the most promising results.
“These results are encouraging, but we are in the early stages of development,” Gu says.
“The next step would be a large animal study to further evaluate the safety and efficacy of the technique.
And while it is much too early to estimate cost, we think that the treatment could be scaled up and would be affordable.”
The paper, “A melanin-mediated cancer immunotherapy patch,” is published in the journal Science Immunology.
More information: Y. Ye el al., “A melanin-mediated cancer immunotherapy patch,” Science Immunology(2017). immunology.sciencemag.org/look … 6/sciimmunol.aan5692